Fiche centre
Peking University First Hospital
Beijing — China
Essais liés21clinical trials
VilleBeijinglocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07164443
Essais cliniques associés
21| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| SEEG RF-TC | Épilepsie | Non applicable | NCT07923058 | SEEG-DRE — Clinical Trial of SEEG for Drug-resistant Epilepsy | NOT_YET_RECRUITING |
| Survodutide | Maladie rénale chronique | Phase 3 | NCT06077864 | A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | COMPLETED |
| Low Dose PF-07328948 | Insuffisance cardiaque | Phase 2 | NCT06991257 | A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) | RECRUITING |
| BBM-L101 Injection | Myopathies | Phase 1 | NCT07874516 | BBM-L101 Gene Therapy in Participants With LGMD2D/R3 | NOT_YET_RECRUITING |
| TAR-200 | Cancer | Phase 3 | NCT06211764 | SunRISe-5 — A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) | ACTIVE_NOT_RECRUITING |
| Pasritamig | Cancer | Phase 3 | NCT07164443 | KLK2-comPAS — A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING |
| TAK-935 | Épilepsie | Phase 2 | NCT03650452 | ELEKTRA — A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies | COMPLETED |
| Soticlestat | Épilepsie | Phase 3 | NCT04940624 | A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome | COMPLETED |
| Soticlestat | Épilepsie | Phase 2 | NCT03635073 | Endymion 1 — A Study of Soticlestat in Adults and Children With Rare Epilepsies | TERMINATED |
| Soticlestat | Épilepsie | Phase 3 | NCT05163314 | A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome | TERMINATED |
| Soticlestat | Épilepsie | Phase 3 | NCT04938427 | A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome | COMPLETED |
| Trontinemab | Alzheimer | Phase 3 | NCT07717411 | PrevenTRON — A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | RECRUITING |
| Ocrelizumab | SEP | Phase 4 | NCT07483450 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| LY4298445 | Lupus | Phase 1 | NCT07276958 | A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) | RECRUITING |
| obinutuzumab (RO5072759) | Lupus | Phase 3 | NCT07767188 | A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial) | NOT_YET_RECRUITING |
| Skeletal muscle biopsy (residual specimen) | Myopathies | À vérifier | NCT06101940 | Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1) | ENROLLING_BY_INVITATION |
| B007 | Myasthénie | Phase 2/3 | NCT06447597 | A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. | RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07169578 | TRONTIER 1 — A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Cevostamab | Lupus | Phase 1 | NCT07629583 | To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | RECRUITING |
| zorevunersen | Épilepsie | Phase 3 | NCT06872125 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04586010 | FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |